NCT03301779: A reported trial by Hemanext
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03301779 |
|---|---|
| Title | Clinical Investigation to Evaluate the New Health Sciences Hemanext® Oxygen Reduction System for Leukoreduced Red Blood Cells With CP2D Anticoagulant and AS-3 Additive - Pivotal Trial |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 27, 2017 |
| Completion date | March 6, 2019 |
| Required reporting date | March 5, 2020, midnight |
| Actual reporting date | Aug. 13, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |